Clinical trial · Interventional
Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC
Randomized Phase II Trial of Two Different Schedules of Docetaxel Plus Cisplatin as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
NCT00319514CI-TRIAL-00001339completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the toxicity and efficacy of docetaxel and cisplatin combination on two schedules in patients with previously untreated, advanced NSCLC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel | Drug | Docetaxel | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Objective response rate
Secondary outcomes (3)
- measure
- Progression-free survival
- measure
- Overall survival
- measure
- Safety
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * histologically or cytologically proven non-small cell lung cancer * no prior chemotherapy or only adjuvant chemotherapy which had been completed \>6 months before registration * ECOG performance status 0 to 2 * measurable lesion(s) * normal marrow, hepatic and renal functions * provision of written informed consent Exclusion Criteria: * active infection or severe comorbidities * history of anaphylaxis of any origin
References
Publications (0)
Data not yet available
No reference posted for this study.